All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

1.1 The burden of schizophrenia and related disorders {#sec006}
-----------------------------------------------------

There is no doubt that schizophrenia is a chronic and severe mental illness that implies a high global disease burden and was ranked among the top 15 leading causes of disability worldwide in 2016 \[[@pone.0195687.ref001]\]. Although schizophrenia is classified as a *low-prevalence disorder* \[[@pone.0195687.ref002]\], its economic burden was estimated to range from 0.02% to 1.65% of gross domestic product \[[@pone.0195687.ref003]\].

To understand the causes of mental disorders, it is essential to measure their frequency \[[@pone.0195687.ref004]\]. While incidence studies are useful for identifying disease risk factors, prevalence studies show the burden of disease in society \[[@pone.0195687.ref005]\]. Knowing the exact extent of disease burden in populations, at local, national or international levels is important to advise governments, health managers, and health professionals to improve development and distribution of health services \[[@pone.0195687.ref006],[@pone.0195687.ref007]\].

In addition to etiological and environmental factors, the variability of the estimated prevalence may also be influenced by the methodological factors of the studies \[[@pone.0195687.ref002]\]. There is a growing consensus that the variability of the prevalence of schizophrenia in epidemiological studies is due partly to the differences in the methodological aspects of the studies \[[@pone.0195687.ref008]\] \[[@pone.0195687.ref009]\], but there are also other factors such as genetic and environmental that do play a role in this variation.

Several studies in the last three decades have published original data on the prevalence of schizophrenia which has been summarized in three systematic reviews \[[@pone.0195687.ref005],[@pone.0195687.ref010],[@pone.0195687.ref011]\]. However, one of the main problems found in previous systematic reviews is the high heterogeneity in the methodological aspects of the studies, which hinders the comparison of results in a homogeneous way \[[@pone.0195687.ref009],[@pone.0195687.ref012]\]. In two systematic reviews of prevalence of schizophrenia, Saha et al.\[[@pone.0195687.ref010]\] and Simeone et al. \[[@pone.0195687.ref011]\] analyzed factors such as diagnostic criteria, case selection methods, and study quality but stated that findings were inconclusive. To our knowledge, none of the previous systematic reviews has performed a meta-analysis including the methodological aspects of the studies.

1.2 The present study {#sec007}
---------------------

The first objective of this study is to develop a comprehensive, systematic review of the existing evidence from the past 25 years (1990--2015) regarding studies that assess the prevalence of psychotic disorders worldwide in order to explore possible sources of heterogeneity in the data by sorting the results according to methodological features. The second objective is to apply a meta-analysis to determine whether the exhibited variation in the prevalence estimate is associated with methodological factors including the following: 1) prevalence type, 2) case-finding setting, 3) method of confirming diagnosis, 4) international classification of diseases, 5) diagnosis category and 6) study quality.

Methods {#sec008}
=======

2.1 Terminology {#sec009}
---------------

In this review, we refer to a "citation/reference" as any unique article from the published literature included in our analyses. We distinguish this from a "study", which refers to any of the different studies performed in an article. Thus, it is important to highlight that one citation can include more than one study and it may generate many items of information on the estimates of the prevalence of psychotic disorders. For example, one citation can offer different estimates concerning the type of prevalence, such as point, 12-month and lifetime, or it may also offer estimates for different locations, such as Sao Paulo, Porto Alegre, or Brasilia within the same citation.

For the preparation of this manuscript, we adhered to the PRISMA statement \[[@pone.0195687.ref013]\] and included a copy of the PRISMA checklist ([S1 Appendix](#pone.0195687.s001){ref-type="supplementary-material"}). This is a proposal to improve systematic reviews and meta-analyses publications consisting of a 27-item instrument that follows the basic structure of a scientific article and details the specific contents that should be reported in each section. We also followed the MOOSE criteria which is another formal reporting guideline for meta-analyses of observational studies. However, we have attached a copy only of the PRISMA checklist as do the majority of the meta-analysis we have revised. This review has been registered in PROSPERO, with registration number [CRD42016047069](http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016047069).

2.2 Literature search: Identification of articles {#sec010}
-------------------------------------------------

To identify relevant articles, we conducted a comprehensive systematic search of the different electronic bibliographic indexes of published literature: Medline, Psycinfo, Scopus, ProQuest Psychology Journals, Embase and Web of Science, with January 1, 1990 to December 31, 2015 as the reference period. Keywords used for this research were: *\"schizophreni\*"*, *"psychosis"*, *"epidemiolog\*"* and *"prevalence"*. Specifically, the keyword combination introduced was as follows: Title (s*chizophreni*\* OR *psychosis*) AND Title (*prevalence* OR *epidemiolog*\*). Searches were carried out between October 2015 and February 2016.

To minimize the possibility of overlooking any relevant data, we also reviewed the bibliographies of each citation identified above, as well as the systematic literature reviews pertinent to our objectives \[[@pone.0195687.ref005],[@pone.0195687.ref010],[@pone.0195687.ref011]\].

2.3 Inclusion criteria {#sec011}
----------------------

The inclusion criteria for articles in the search were: (i) reported prevalence rates of psychotic disorders, (ii) general population or attended population studies, (iii) original studies with primary data, and (iv) period of publication from the year 1990 to 2015, (v) articles published in English or Spanish.

2.4 Selection process articles: Flow diagram {#sec012}
--------------------------------------------

A flow diagram of the search strategy for study inclusion is shown in [Fig 1](#pone.0195687.g001){ref-type="fig"}. At the first stage, we identified 2439 initial citations from the published literature. After identification and removal of duplicate citations (n = 1332) and citations without original data (n = 714), a total of 393 unique citations met potential inclusion for this review. The defined inclusion criteria were applied to the title, and where necessary, abstracts for these citations were revised by two researchers (BMK, CM), independently. The reviewers agreed that 65 citations "met inclusion criteria" and a further 328 citations "did not meet inclusion criteria" for the review. Thus, at the eligibility stage, the full text of the article was obtained for any citation that met inclusion criteria. From the electronic database search, 59 citations met the inclusion criteria for the systematic review following scrutiny of the full text. However, these results were extended through manual bibliography checks of the previously selected articles. With this procedure, 14 additional valid articles were included. In total, the number of articles included in this review rose to 73 (59+14) which provided relevant prevalence data.

![Flow diagram (selection strategy) of included studies from 1990 to 2015.](pone.0195687.g001){#pone.0195687.g001}

2.5 Data extraction {#sec013}
-------------------

All manuscripts were retrieved in paper or electronic format, with all necessary permissions granted prior to their distribution. Once an article was included in this review, the information was extracted in a card for each article. The cards for these articles are available as supporting information in [S2 Appendix](#pone.0195687.s002){ref-type="supplementary-material"}. Card for each article.

We distinguished the following types of variables:

1.  Citation-level variables: article reference number \[ID\], first author, year of publication and country.

2.  Middle-level or meta-variables (methodological issues): 1) case-finding setting (general population/attended in health and/or social services), 2) method of confirming diagnosis (Composite International Diagnostic Interview \[CIDI\]/Schedules for Clinical Assessment in Neuropsychiatry \[SCAN\]/Structured Clinical Interview for DSM-IV \[SCID\]/clinical diagnoses/others), 3) international classification of diseases (International Classification of Diseases \[ICD\]/ Diagnostic and Statistic Manual of Mental Disorders \[DSM\], both), 4) diagnostic categories (schizophrenia/non-affective psychosis/schizophrenia and related disorders/probable psychotic disorder, 5) study quality (1--16) and 6) prevalence type (point/12-month/lifetime).

3.  Rate-level variables: number of cases (numerator), population size (reported denominator), prevalence rate by 1000 persons.

[S1 Table](#pone.0195687.s003){ref-type="supplementary-material"} provides descriptions of the variables we used to analyze the studies.

To assess possible bias in prevalence reporting, the study quality was given for certain features following the criteria of Saha et al. \[[@pone.0195687.ref010]\]. Details of the quality scores used in this review are provided in [S2 Table](#pone.0195687.s004){ref-type="supplementary-material"}.

2.6 Data analysis {#sec014}
-----------------

Subsequently, data extraction was managed using a Microsoft Excel file where the categories of data to be collected were examined and agreed on beforehand. The document screening was carried out by two independent reviewers (BMK, CM) who checked all data used in the analysis. When disagreements arose, these were resolved through consensus by a third co-author (LPE).

### 2.6.1 Identification of relevant data {#sec015}

Prevalence estimates were sorted through the application of sequential filters. To classify relevant data in order to identify all citations which included suitable data for any given analysis, we classified the studies by the following: case-finding setting; method of confirming diagnosis; international classification of diseases; diagnosis categories; and study quality. For this classification, many different analyses could be permuted concerning the type of prevalence rate (point/12-month/lifetime). For each, we identified and recorded citations that contributed relevant rate data and extracted this to a separate analysis.

### 2.6.2 Descriptive analyses {#sec016}

This included descriptive study characteristics reporting the studies counts and percentage. Descriptive statistics, including means, standard deviations, median, ranges, quantiles (10%, 25%, 75%, 90%) and interquartile ranges (IQRs) were used to summarize prevalence estimates. The variation of the estimated rates and any other relevant information (where available) was presented. For each methodological variable we presented the global, point, 12-month and lifetime prevalence rate.

### 2.6.3 Meta-analyses {#sec017}

First, we performed bivariate analyses. We included all independent variables measured and then excluded (step by step) from the model those variables that obtained a significance at P\<0.05 (results not shown).

In the meta-analysis, we estimated the mean effect (mean prevalence) in all studies with a 95% confidence interval (CI). We also estimated the mean prevalence depending on the period of study (point, 12 months and lifetime). We used random-effects meta-regression to estimate the effects of meta-level (methodological) explanatory variables on the outcome of interest. We selected the random effects model for this study assuming that the studies included in the meta-analysis were conducted out in populations that might differ between them. Statistical heterogeneity was evaluated using *I*^2^. In addition, we calculated the *Q* statistic and its *P* value. In this way, we obtained the mean prevalence (unweighted) because we considered all the articles to have the same weight. Thus, we determined which variables were associated independently with the mean effect of the prevalence of psychotic disorders and the proportion of the variance that is explained in the final adjusted model. P\<0.05 was set as the limit of statistical significance of the coefficients.

Unless otherwise stated, all prevalence rates are expressed per 1000 persons with their 95% CI where available.

### 2.6.4 Publication bias {#sec018}

To inspect evidence of publication bias we conducted visual inspection of funnel plots and used Egger's test for bias in meta-analyses\[[@pone.0195687.ref014]\].

All statistical analyses were performed with the open-source software environment R 2.12.0 \[[@pone.0195687.ref015]\]. Calculation of mean effect and random-effects meta-regression was performed with the metaphor package \[[@pone.0195687.ref016]\].

Results {#sec019}
=======

3.1 Characteristics of the studies {#sec020}
----------------------------------

We identified 73 articles which provided original data on the prevalence of psychotic disorders worldwide, between 1990 and 2015 \[[@pone.0195687.ref011],[@pone.0195687.ref017]--[@pone.0195687.ref088]\]. Key features of these articles sorted by first author are provided in [Table 1](#pone.0195687.t001){ref-type="table"}.

10.1371/journal.pone.0195687.t001

###### Characteristics of the 101 studies included in the systematic review.

![](pone.0195687.t001){#pone.0195687.t001g}

  ID   First author, year     Country               Case finding setting   Method of confirming diagnosis   International classification   Diagnostic category   Study quality[^1^](#t001fn006){ref-type="table-fn"}   Prevalence type   Population   Case    Rate[^2^](#t001fn007){ref-type="table-fn"}   LCI     UCI
  ---- ---------------------- --------------------- ---------------------- -------------------------------- ------------------------------ --------------------- ----------------------------------------------------- ----------------- ------------ ------- -------------------------------------------- ------- -------
  17   Agius, 2009            UK (South East)       attended               clinical                         DSM                            SRD                   7                                                     Point             21350        42      1.97                                         1.42    2.66
  17   Agius, 2009            UK (North East)       attended               clinical                         DSM                            SRD                   7                                                     Point             43829        137     3.13                                         2.62    3.69
  17   Agius, 2009            UK (North West)       attended               clinical                         DSM                            SRD                   7                                                     Point             57414        122     2.12                                         1.76    2.54
  17   Agius, 2009            UK (South West)       attended               clinical                         DSM                            SRD                   7                                                     Point             61778        331     5.36                                         4.80    5.97
  18   Almeida, 1997          Porto-Alegre          general population     SCID                             DSM                            NAP                   15                                                    Lifetime          2384         57      24.00                                        4.36    43.64
  18   Almeida, 1997          Sao Paulo             general population     SCID                             DSM                            NAP                   15                                                    Lifetime          1742         16      9.18                                         4.70    13.66
  18   Almeida,1997           Brasilia              general population     SCID                             DSM                            NAP                   15                                                    Lifetime          2345         7       3.24                                         0.94    5.54
  19   Andrade, 2002          Brazil                general population     CIDI                             ICD                            NAP                   13                                                    12-month          1464         12      8.20                                         3.58    12.82
  19   Andrade, 2002          Brazil                general population     CIDI                             ICD                            NAP                   13                                                    Point             1464         10      6.83                                         2.61    11.05
  19   Andrade, 2002          Brazil                general population     clinical                         ICD                            NAP                   13                                                    Lifetime          1464         28      19.13                                        12.11   26.14
  20   Andrews, 2001          Australia             general population     CIDI                             both                           NAP                   15                                                    Point             10641        43      4.04                                         2.84    5.25
  20   Andrews, 2001          Australia             general population     CIDI                             both                           NAP                   15                                                    12-month          10641        43      4.04                                         2.84    5.25
  21   Arajarvi, 2005         Finland               general population     SCID                             ICD                            Schizophrenia         14                                                    Lifetime          12368        191     15.44                                        13.27   17.62
  22   Awas, 1999             Ethiopia              general population     CIDI                             ICD                            Schizophrenia         15                                                    Point             10468        63      6.02                                         4.54    7.50
  23   Bijl, 1998             Holland               general population     CIDI                             DSM                            Schizophrenia         16                                                    12-month          7076         14      1.98                                         0.94    3.01
  23   Bijl, 1998             Holland               general population     CIDI                             DSM                            Schizophrenia         16                                                    Point             7076         14      1.98                                         0.94    3.01
  23   Bijl, 1998             Holland               general population     CIDI                             DSM                            Schizophrenia         16                                                    Lifetime          7076         28      3.96                                         2.49    5.42
  24   Binbay, 2012           Turkey                general population     CIDI                             DSM                            Schizophrenia         13                                                    Lifetime          4011         30      7.48                                         4.81    10.15
  25   Chien, 2004            Taiwan                general population     clinical                         ICD                            Schizophrenia         12                                                    12-month          137914       607     4.40                                         4.05    4.75
  26   Cho, 2007              Korea                 general population     CIDI                             DSM                            Schizophrenia         13                                                    Lifetime          6275         13      2.07                                         0.95    3.20
  26   Cho,2007               Korea                 general population     CIDI                             DSM                            Schizophrenia         13                                                    12-month          6275         13      2.07                                         0.95    3.20
  27   Clayer, 1995           Australia             general population     others                           DSM                            Schizophrenia         13                                                    12-month          1009         8       7.93                                         2.46    13.40
  28   Cohidon, 2009          France                general population     others                           ICD                            Probable              7                                                     Lifetime          40157        1084    26.99                                        25.41   28.58
  30   Díaz Martínez, 2003    Mexico                general population     CIDI                             ICD                            Schizophrenia         7                                                     12-month          608          12      19.74                                        8.68    30.79
  29   Díaz-Cruz, 2004        Spain                 general population     CIDI                             DSM                            NAP                   12                                                    Point             800          2       2.50                                         -0.96   5.96
  31   Dourado, 2001          Azores                Atended                others                           both                           Schizophrenia         10                                                    Lifetime          4332         14      2.40                                         0.94    3.86
  32   Favarelli, 2004        Italy                 general population     SCID                             DSM                            NAP                   14                                                    Lifetime          2363         17      7.19                                         3.79    10.60
  33   Fekadu, 2004           Ethiopia              general population     CIDI                             ICD                            Schizophrenia         10                                                    Point             2281         1       0.44                                         -0.42   1.30
  34   Fors, 2007             Sweden                Atended                clinical                         both                           Schizophrenia         10                                                    12-month          64041        237     3.70                                         3.23    4.17
  35   Gigantesco, 2006       Italy                 general population     others                           ICD                            Probable              15                                                    Point             267          1       3.75                                         -3.58   11.07
  35   Gigantesco, 2006       Italy                 general population     others                           ICD                            Probable              15                                                    12-month          267          1       3.75                                         -3.58   11.07
  35   Gigantesco, 2006       Italy                 general population     others                           ICD                            Probable              15                                                    Lifetime          267          2       7.49                                         -2.85   17.83
  36   Goldner, 2003          Canada                Atended                clinical                         both                           Schizophrenia         8                                                     12-month          11516        48      4.17                                         2.99    5.34
  37   Gureje, 2010           Nigeria               general population     CIDI                             DSM                            NAP                   11                                                    Lifetime          4985         105     21.06                                        17.08   25.05
  37   Gureje, 2010           Nigeria               general population     CIDI                             DSM                            NAP                   11                                                    12-month          4985         55      11.03                                        8.13    13.93
  38   Hosain, 2007           Bangladesh            general population     clinical                         DSM                            NAP                   10                                                    Point             766          9       11.75                                        4.12    19.38
  39   Hovatta, 1997          Finland               Atended                clinical                         DSM                            SRD                   12                                                    Lifetime          4998478      29091   5.82                                         5.75    5.88
  40   Jablensky, 2000        Australia             Atended                SCAN                             ICD                            Probable              13                                                    Point             980          5       5.10                                         0.64    9.56
  41   Jeffreys, 1997         UK                    Atended                clinical                         DSM                            Probable              14                                                    Point             115294       588     5.10                                         4.69    5.51
  42   Jenkins, 1997          UK                    general population     SCAN                             ICD                            NAP                   15                                                    12-month          10108        40      3.96                                         2.73    5.18
  43   Jörgensen, 2013        Sweden                attended               clinical                         ICD                            Schizophrenia         10                                                    12-month          946381       3502    3.70                                         3.58    3.82
  44   KaKe, 2008             Australia             attended               clinical                         ICD                            Schizophrenia         10                                                    12-month          3736269      11956   3.20                                         3.14    3.26
  45   Kebede, 1999           Ethiopia              general population     CIDI                             ICD                            Schizophrenia         12                                                    Point             10203        31      3.04                                         1.97    4.11
  46   Kebede, 2003           Ethiopia              general population     CIDI                             ICD                            Schizophrenia         11                                                    Lifetime          68378        321     4.69                                         4.18    5.21
  47   Kendler, 1996          USA                   general population     CIDI                             DSM                            SRD                   14                                                    Lifetime          8098         89      10.99                                        8.72    13.26
  49   Kessler, 1994          USA                   general population     CIDI                             DSM                            NAP                   15                                                    Lifetime          8098         57      7.04                                         5.22    8.86
  49   Kessler, 1994          USA                   general population     CIDI                             DSM                            NAP                   15                                                    12-month          8098         40      4.94                                         3.41    6.47
  48   Kessler, 2005          USA                   general population     CIDI                             DSM                            NAP                   13                                                    Lifetime          9282         29      3.12                                         1.99    4.26
  48   Kessler, 2005          USA                   general population     CIDI                             DSM                            NAP                   13                                                    12-month          9282         46      5.00                                         3.63    6.60
  50   Kodesh, 2012           Israel                attended               clinical                         ICD                            SRD                   8                                                     12-month          8848         44      4.97                                         3.51    6.44
  51   Kringlen, 2001         Norway                general population     CIDI                             DSM                            NAP                   12                                                    Lifetime          2066         8       3.87                                         1.19    6.55
  51   Kringlen, 2001         Norway                general population     CIDI                             DSM                            NAP                   12                                                    12-month          2066         4       1.94                                         0.04    3.83
  52   Kringlen, 2006         Norway                general population     CIDI                             DSM                            NAP                   15                                                    12-month          1080         3       2.78                                         -0.36   5.92
  52   Kringlen, 2006         Norway                general population     CIDI                             DSM                            NAP                   15                                                    Lifetime          1080         4       3.70                                         0.08    7.33
  53   Kurihara, 2005         Indonesia             general population     SCID                             DSM                            Schizophrenia         11                                                    Point             8546         36      4.21                                         2.84    5.59
  54   Lindström, 1997        Sweden                attended               clinical                         DSM                            Schizophrenia         9                                                     12-month          64886        273     4.21                                         3.71    4.71
  55   McConnell, 2002        EIRE                  general population     SCAN                             ICD                            Schizophrenia         10                                                    12-month          1242         5       4.03                                         0.50    7.55
  56   McCreadie, 1997        Nishsdale             attended               others                           ICD                            Schizophrenia         12                                                    Point             57831        161     2.78                                         2.35    3.21
  56   McCreadie, 1997        Norwood               attended               others                           ICD                            Schizophrenia         12                                                    Point             23007        52      2.24                                         1.63    2.85
  56   McCreadie, 1997        Nunhead               attended               others                           ICD                            Schizophrenia         12                                                    Point             29448        102     3.46                                         2.79    4.13
  57   Moreno, 2008           Spain                 attended               clinical                         ICD                            SRD                   9                                                     12-month          270629       774     2.86                                         -0.90   6.62
  58   Moreno-Küstner, 2015   Spain                 attended               clinical                         ICD                            SRD                   11                                                    12-month          265229       1053    3.97                                         0.84    3.40
  59   Morgan, 2014           Australia             attended               others                           ICD                            NAP                   13                                                    12-month          4928         12      3.45                                         3.73    4.21
  59   Morgan, 2014           Australia             attended               others                           ICD                            NAP                   13                                                    Point             4928         10      3.10                                         1.01    3.73
  60   Myles-Worsley, 1999    Micronesia            attended               others                           DSM                            SRD                   10                                                    Lifetime          13750        262     19.90                                        17.57   22.23
  61   Nimgaonkar, 2000       Canada                attended               clinical                         DSM                            Schizophrenia         9                                                     12-month          8542         11      1.29                                         0.94    1.64
  62   Ortega, 1995           Spain                 general population     others                           DSM                            SRD                   14                                                    Point             793          1       1.26                                         -1.21   3.73
  8    Perälä, 2007           Finland               general population     SCID                             DSM                            Schizophrenia         16                                                    Lifetime          8028         70      8.72                                         6.69    10.75
  63   Perälä, 2008           Finland. North        general population     CIDI                             both                           Schizophrenia         10                                                    Lifetime          8028         148     18.44                                        15.49   21.38
  63   Perälä, 2008           Finland. South        general population     CIDI                             both                           Schizophrenia         10                                                    Lifetime          8028         74      9.22                                         7.13    11.31
  63   Perälä, 2008           Finland. East         general population     CIDI                             both                           Schizophrenia         10                                                    Lifetime          8028         86      10.71                                        8.46    12.96
  63   Perälä, 2008           Finland. South-west   general population     CIDI                             both                           Schizophrenia         10                                                    Lifetime          8028         51      6.35                                         4.61    8.09
  63   Perälä, 2008           Finland. West         general population     CIDI                             both                           Schizophrenia         10                                                    Lifetime          8028         63      7.85                                         5.92    9.78
  64   Phanthunane, 2010      Thailand              general population     others                           both                           SRD                   12                                                    Lifetime          11700        103     8.80                                         7.11    10.50
  65   Phillips, 2004         China                 general population     clinical                         ICD                            Schizophrenia         11                                                    Point             19223        90      4.68                                         3.72    5.65
  66   Phillips, 2009         China                 general population     SCID                             DSM                            Schizophrenia         16                                                    Point             63004        492     7.81                                         7.12    8.50
  67   Pringle, 1995          Ireland               attended               clinical                         DSM                            Schizophrenia         11                                                    12-month          37272        83      2.22                                         1.77    2.76
  68   Ran, 2003              China                 general population     clinical                         ICD                            Schizophrenia         14                                                    Lifetime          89512        367     4.10                                         3.68    4.52
  69   Roca, 1999             Spain                 general population     SCAN                             ICD                            SRD                   9                                                     Point             697          3       5.00                                         0.89    12.53
  70   Ruggeri, 2000          Italy                 attended               clinical                         ICD                            NAP                   13                                                    12-month          62240        212     3.41                                         2.95    3.86
  71   Schrier, 2001          Netherlands           attended               clinical                         DSM                            Schizophrenia         9                                                     Point             337362       713     2.11                                         1.96    2.27
  72   Scully, 2004           Ireland               attended               SCID                             DSM                            Schizophrenia         15                                                    Lifetime          29542        115     3.59                                         3.21    4.67
  73   Shivashankar, 2013     Scotland              general population     clinical                         ICD                            Schizophrenia         8                                                     Point             205          1       4.88                                         -4.66   14.42
  74   Singleton, 2003        UK                    general population     SCAN                             DSM                            Probable              13                                                    12-month          8886         44      4.95                                         3.49    6.41
  75   Suvisaari, 2009        Finland               general population     CIDI                             DSM                            Schizophrenia         11                                                    Lifetime          8028         66      8.22                                         0.74    2.50
  76   Thornicroft, 1998      UK                    attended               SCAN                             ICD                            NAP                   13                                                    12-month          80285        618     7.70                                         7.09    8.30
  77   Tizon, 2007            Spain                 attended               clinical                         DSM                            SRD                   11                                                    12-month          21236        97      4.57                                         3.66    5.47
  78   Tizón, 2009            Spain                 attended               clinical                         DSM                            SRD                   9                                                     Lifetime          103615       477     4.60                                         4.19    5.02
  79   Vanasse, 2012          Canada                attended               clinical                         ICD                            Schizophrenia         9                                                     Lifetime          5996925      35585   5.93                                         5.87    6.00
  79   Vanasse, 2012          Canada                attended               clinical                         ICD                            Schizophrenia         9                                                     12-month          5996925      7988    1.33                                         1.30    1.36
  80   Vicente, 2004          Chile                 general population     CIDI                             DSM                            NAP                   13                                                    12-month          2978         15      5.04                                         2.49    7.58
  80   Vicente, 2004          Chile                 general population     CIDI                             DSM                            NAP                   13                                                    Point             2978         15      5.04                                         2.49    7.58
  81   Vicente, 2006          Chile                 general population     CIDI                             DSM                            NAP                   13                                                    12-month          2978         21      7.05                                         4.05    10.06
  81   Vicente, 2006          Chile                 general population     CIDI                             DSM                            NAP                   13                                                    Lifetime          2978         54      18.13                                        13.34   22.93
  82   Villaverde, 1993       Spain                 general population     others                           DSM                            Schizophrenia         13                                                    Point             660          4       6.06                                         0.14    11.98
  83   Waldo, 1999            Micronesia            attended               SCID                             DSM                            Schizophrenia         10                                                    Point             3235         22      6.80                                         3.97    9.63
  84   Widerlöv, 1997         Sweden                attended               clinical                         DSM                            Schizophrenia         11                                                    12-month          64886        273     4.21                                         3.71    4.71
  85   Wu, 2006               USA                   attended               clinical                         ICD                            Schizophrenia         7                                                     12-month          6800000      34680   5.10                                         5.05    5.15
  86   Xiang, 2008            China                 general population     CIDI                             ICD                            Schizophrenia         15                                                    Lifetime          5926         29      4.89                                         3.12    6.67
  87   Yang, 2014             China                 general population     CIDI                             ICD                            Schizophrenia         13                                                    Point             1984         5       2.52                                         0.31    4.73
  88   Youssef, 1999          Ireland               attended               clinical                         DSM                            Schizophrenia         11                                                    12-month          21520        72      3.39                                         2.62    4.17

Attended: population attended in mental and/or social services.

SCID: Structure Clinical Interview for DSM-IV, CIDI: Composite International Diagnostic Interview, SCAN: Schedules for Clinical Assessment in Neuropsychiatry.

ICD: International Classification of Diseases, DSM: Diagnostic and Statistic Manual of Mental Disorders. Both: ICD and DSM.

NAP: Non-affective psychosis. SRD: Schizophrenia and related disorders. Probable: Probable psychotic disorders

LCI = Lower bound of 95% Confidence Interval; UCI: Upper bound of 95% Confidence Interval.

^1^Study quality according to criteria outlined in methodology. Min = 0, Max = 16.

^2^ Prevalence rate per 1.000.

The articles analyzed used different population settings to detect cases to be included in the studies; the majority of them (60.27%) were conducted in the general population and the rest in patients attended in health and/or social services. The method of confirming the diagnosis in the cases included in the studies in these articles was distributed as follows: 35.62% used the clinical diagnoses based on the criterion or clinical judgment of the referring physician, followed by 31.51% that used the CIDI, 10.96% used the SCID for DSM-IV, 8.22% used the SCAN and 13.7% included a variety of instruments such as DIGS, DIP, DIS, OPCRIT, or SADS. With respect to the classification of diseases on which the diagnoses were based, it is of note that 50.68% of the studies used the DSM in its versions III, III-R, IV and IV-TR, followed by 41.10% the ICD in its 7^th^, 8^th^, 9^th^ and 10^th^ versions. On several occasions both were used. The categories concerning the type of diagnosis in the studies were the following: 53.42% included only schizophrenia, 23.29% included patients with non-affective psychosis, 16.44% included patients diagnosed with schizophrenia and related disorders, and 6.85% included patients with a diagnosis of probable psychotic disorder. Quality of the studies. The mean quality score obtained through application of the Saha et al. criteria for all included articles was 11.75 points (of a possible total of 16) with all studies obtaining scores greater than 7 points.

3.2 Prevalence of psychotic disorders by subgroup {#sec021}
-------------------------------------------------

These 73 articles provided 101 prevalence rates based on an estimated total of 134,763 potentially overlapping cases. All data are provided in [Table 1](#pone.0195687.t001){ref-type="table"}.

Tables [2](#pone.0195687.t002){ref-type="table"}, [3](#pone.0195687.t003){ref-type="table"}, [4](#pone.0195687.t004){ref-type="table"} and [5](#pone.0195687.t005){ref-type="table"} show the moments and quantiles for combined prevalence estimates for persons and by factors analyzed, showing the median prevalence for the 101 studies and by the four types of prevalence (global, point, 12-month and lifetime), for both sexes.

10.1371/journal.pone.0195687.t002

###### Quantiles and moments of global prevalence per 1,000 persons.

![](pone.0195687.t002){#pone.0195687.t002g}

  Methodological variables                       Number of studies   Quantiles   Mean   Standard deviation   IQR                          
  ---------------------------------------------- ------------------- ----------- ------ -------------------- ------ ------- ------ ------ ------
                                                 101                 2.11        3.24   4.60                 7.2    11.03   6.18   5.10   3.95
  **Case-finding method**                                                                                                                 
  General population                             65                  2.24        3.87   5.00                 8.22   17.06   7.24   5.68   4.35
  Attended in any health service                 36                  2.11        2.84   3.64                 5.00   5.88    4.25   3.36   3.68
  **Method of confirming diagnosis**                                                                                                      
  SCID                                           10                  3.56        4.86   7.50                 9.07   16.30   9.02   6.38   4.21
  CIDI                                           39                  2.05        3.08   5.00                 8.02   16.30   6.62   5.11   4.94
  SCAN                                           6                   3.99        4.26   4.98                 5.08   6400    5.12   1.36   0.82
  Clinical diagnosis                             31                  2.11        3.16   4.17                 4.93   5.82    4.56   3.30   1.76
  Others                                         15                  2.30        2.94   3.75                 7.71   15.46   6.89   7.20   4.77
  **International classification of diseases**                                                                                            
  ICD                                            38                  2.70        3.41   4.25                 5.73   10.37   5.95   5.42   2.31
  DSM                                            52                  1.29        3.10   4.20                 7.00   21.00   6.10   5.03   4.23
  Both                                           11                  3.70        4.04   6.35                 9.01   10.71   7.25   4.60   5.00
  **Diagnosis category**                                                                                                                  
  Schizophrenia only                             49                  2.05        2.78   4.21                 6.35   8.82    5.30   4.00   3.57
  Schizophrenia and related disorders            15                  2.03        2.99   4.60                 5.59   10.12   5.69   4.68   2.60
  Non-affective psychosis                        30                  3.07        3.51   5.02                 8.07   18.23   7.38   5.86   4.56
  Probable schizophrenia                         7                   3.74        4.35   5.10                 6.30   15.29   8.16   8.40   1.95

IQR: Interquartile range. SCID: Structure Clinical Interview for DSM-IV, CIDI: Composite International Diagnostic Interview, SCAN: Schedules for Clinical Assessment in Neuropsychiatry.

ICD: International Classification of Diseases, DSM: Diagnostic and Statistic Manual of Mental Disorders

10.1371/journal.pone.0195687.t003

###### Quantiles and moments of point prevalence per 1,000 persons.

![](pone.0195687.t003){#pone.0195687.t003g}

  Methodological variables                       Number of studies   Quantiles   Mean   Standard deviation   IQR                           
  ---------------------------------------------- ------------------- ----------- ------ -------------------- ------ ------- ------ ------- ------
                                                 30                  1.97        2.51   3.89                 5.10   6.80    4.17   2.30    2.60
  **Case-finding method**                                                                                                                  
  General population                             18                  1.76        2.65   4.44                 5.77   7.12    4.54   2.64    3.12
  Attended in any health service                 12                  2.11        2.11   3.11                 5.10   5.33    3.61   1.59    2.89
  **Method of confirming diagnosis**                                                                                                       
  SCID                                           3                   4.73        5.50   6.80                 7.30   7.60    6.27   1.86    1.80
  CIDI                                           9                   1.67        2.50   3.04                 5.04   6.18    3.60   2.06    2.54
  SCAN                                           2                   5.01        5.02   5.05                 5.08   5.09    5.05   0.07    0.05
  Clinical diagnosis                             9                   2.10        3.54   4.70                 5.38   11.70   4.57   3.03    2.98
  Others                                         7                   1.85        2.51   3.10                 3.60   4.67    3.24   1.49    1.09
  **International classification of diseases**                                                                                             
  ICD                                            14                  2.32        2.84   3.60                 4.97   5.74    3.84   1.683   2.12
  DSM                                            15                  1.30        3.11   5.00                 6.65   11.70   4.84   2.84    3.59
  Both                                           1                   4.04        4.04   4.04                 4.04   4.04    4.04   \-      0.00
  **Diagnosis category**                                                                                                                   
  Schizophrenia only                             15                  2.03        2.38   3.46                 5.45   6.50    3.93   2.07    3.07
  Schizophrenia and related disorders            6                   1.61        2.01   2.63                 4.53   5.18    3.14   1.69    2.52
  Non-affective psychosis                        6                   2.80        3.34   4.54                 6.38   9.29    5.54   3.40    3.05
  Probable schizophrenia                         3                   4.02        4.42   5.10                 5.10   5.10    4.65   0.78    0.68

IQR: Interquartile range. SCID: Structure Clinical Interview for DSM-IV, CIDI: Composite International Diagnostic Interview, SCAN: Schedules for Clinical Assessment in Neuropsychiatry.

ICD: International Classification of Diseases, DSM: Diagnostic and Statistic Manual of Mental Disorders

10.1371/journal.pone.0195687.t004

###### Quantiles and moments of 12-month prevalence per 1,000 persons.

![](pone.0195687.t004){#pone.0195687.t004g}

  Methodological variables                       Number of studies   Quantiles   Mean   Standard deviation   IQR                           
  ---------------------------------------------- ------------------- ----------- ------ -------------------- ------ ------- ------ ------- ------
                                                 37                  2.03        3.20   4.03                 4.97   7.79    4.69   3.24    1.77
  **Case-finding method**                                                                                                                  
  General population                             19                  2.05        3.43   4.40                 6.04   8.76    5.57   4.15    2.61
  Attended in any health service                 18                  1.95        3.25   3.70                 4.20   5.01    3.75   1.45    0.96
  **Method of confirming diagnosis**                                                                                                       
  SCID                                           \-                  \-          \-     \-                   \-     \-      \-     \-      \-
  CIDI                                           13                  2.00        2.77   4.94                 7.05   10.47   5.92   4.95    4.27
  SCAN                                           4                   3.98        4.00   4.49                 5.63   6.87    5.16   1.75    1.63
  Clinical diagnosis                             17                  1.86        3.00   3.70                 4.21   4.73    3.57   1.12    1.01
  Others                                         3                   3.51        3.00   3.75                 5.84   7.09    5.04   2.50    2.24
  **International classification of diseases**                                                                                             
  ICD                                            16                  3.02        3.44   3496                 5.00   7.95    5.23   4.22    1.57
  DSM                                            18                  1.97        2.36   4.21                 5.00   7.31    4.32   2.45    2.63
  Both                                           3                   3.77        3.87   4.04                 4.10   4.14    3.97   0.24    0.23
  **Diagnosis category**                                                                                                                   
  Schizophrenia only                             17                  1.72        2.22   3.70                 4.21   6.23    4.51   4.238   1.99
  Schizophrenia and related disorders            4                   3.19        3.69   4.27                 4.67   4.85    4.09   0.91    0.98
  Non-affective psychosis                        14                  2.88        3.42   4.49                 6.55   8.05    5.12   2.52    3.13
  Probable schizophrenia                         2                   3.87        4.05   4.35                 4.65   4.83    4.35   0.85    0.60

IQR: Interquartile range. SCID: Structure Clinical Interview for DSM-IV, CIDI: Composite International Diagnostic Interview, SCAN: Schedules for Clinical Assessment in Neuropsychiatry.

ICD: International Classification of Diseases, DSM: Diagnostic and Statistic Manual of Mental Disorders

10.1371/journal.pone.0195687.t005

###### Quantiles and moments of lifetime prevalence per 1,000 persons.

![](pone.0195687.t005){#pone.0195687.t005g}

  Methodological variables                       Number of studies   Quantiles   Mean    Standard deviation   IQR                              
  ---------------------------------------------- ------------------- ----------- ------- -------------------- ------- -------- ------- ------- -------
                                                 34                  3.62        4.63    7.49                 10.92   19.67    9.57    6.69    6.29
  **Case-finding method**                                                                                                                      
  General population                             28                  3.82        4.84    8.03                 12.10   19.71    10.11   6.73    7.26
  Attended in any health service                 6                   2.00        3.84    5.21                 5.91    12.92    7.04    6.44    2.06
  **Method of confirming diagnosis**                                                                                                           
  SCID                                           7                   3.45        5.39    8.72                 12.31   18.87    10.20   7.33    6.92
  CIDI                                           17                  3.80        4.69    7.48                 10.71   18.25    8.75    5.60    6.02
  SCAN                                           \-                  \-          \-      \-                   \-      \-       \-      \-      \-
  Clinical diagnosis                             5                   4.30        4.60    5.82                 5.93    13.85    7.92    6.31    1.33
  Others                                         6                   4.44        7.49    8.80                 19.90   24.16    13.12   10.05   12.41
  **International Classification of diseases**                                                                                                 
  ICD                                            8                   4.52        4.84    6.71                 16.36   21.49    11.08   8.49    11.52
  DSM                                            19                  3.52        3.91    7.19                 10.09   20--13   9.09    6.69    6.17
  Both                                           7                   4.77        7.10    8.80                 9.97    13.80    9.11    4.90    2.86
  Others                                         \-                  \-          \-      \-                   \-      \-       \-      \-      \-
  **Diagnosis category**                                                                                                                       
  Schizophrenia only                             17                  3.11        4.10    6.35                 8.72    12.60    7.30    4.41    4.62
  Schizophrenia and related disorders            5                   5.09        5.82    8.80                 10.99   16.33    10.02   6.06    5.17
  Non-affective psychosis                        10                  3.66        4.66    8.19                 18.88   21.36    11.66   8.03    14.21
  Probable schizophrenia                         2                   9.44        12.37   17.24                22.12   25.04    17.24   13.79   9.75

IQR: Interquartile range. SCID: Structure Clinical Interview for DSM-IV, CIDI: Composite International Diagnostic Interview, SCAN: Schedules for Clinical Assessment in Neuropsychiatry.

ICD: International Classification of Diseases, DSM: Diagnostic and Statistic Manual of Mental Disorders

From the 101 prevalence estimates, the median global prevalence for persons across these studies was 4.6 per 1000, and the 10% and 90% quantiles ranged from 2.11 to 11.03 per 1000, respectively (a 5.2-fold difference) ([Table 2](#pone.0195687.t002){ref-type="table"}). A total of 25 articles \[[@pone.0195687.ref017],[@pone.0195687.ref019],[@pone.0195687.ref020],[@pone.0195687.ref022],[@pone.0195687.ref023],[@pone.0195687.ref029],[@pone.0195687.ref033],[@pone.0195687.ref035],[@pone.0195687.ref038],[@pone.0195687.ref040],[@pone.0195687.ref041],[@pone.0195687.ref045],[@pone.0195687.ref053],[@pone.0195687.ref056],[@pone.0195687.ref059],[@pone.0195687.ref062],[@pone.0195687.ref065],[@pone.0195687.ref066],[@pone.0195687.ref069],[@pone.0195687.ref071],[@pone.0195687.ref073],[@pone.0195687.ref080],[@pone.0195687.ref082],[@pone.0195687.ref083],[@pone.0195687.ref087]\] estimated 30 rates of point prevalence of psychotic disorders and the median across these studies was 3.89 per 1000, and the 10% and 90% quantiles ranged from 1.98 to 6.8 per 1000, respectively (a 3.43-fold difference) ([Table 3](#pone.0195687.t003){ref-type="table"}). Thirty-six of the articles \[[@pone.0195687.ref019],[@pone.0195687.ref020],[@pone.0195687.ref023],[@pone.0195687.ref025],[@pone.0195687.ref026],[@pone.0195687.ref027],[@pone.0195687.ref030],[@pone.0195687.ref034],[@pone.0195687.ref035],[@pone.0195687.ref036],[@pone.0195687.ref037],[@pone.0195687.ref042],[@pone.0195687.ref043],[@pone.0195687.ref044],[@pone.0195687.ref048],[@pone.0195687.ref049],[@pone.0195687.ref050],[@pone.0195687.ref051],[@pone.0195687.ref052],[@pone.0195687.ref054],[@pone.0195687.ref055],[@pone.0195687.ref057],[@pone.0195687.ref058],[@pone.0195687.ref059],[@pone.0195687.ref061],[@pone.0195687.ref067],[@pone.0195687.ref070],[@pone.0195687.ref074],[@pone.0195687.ref076],[@pone.0195687.ref077],[@pone.0195687.ref079],[@pone.0195687.ref080],[@pone.0195687.ref081],[@pone.0195687.ref084],[@pone.0195687.ref085],[@pone.0195687.ref088]\] considered 37 estimates rates of the 12-month prevalence. The median 12-month prevalence across these studies was 4.03 per 1000 persons, and the 10% and 90% quantiles ranged from 2.03 to 7.79 per 1000 (a 3.84-fold difference) ([Table 4](#pone.0195687.t004){ref-type="table"}). Lifetime prevalence was considered in 28 of the articles \[[@pone.0195687.ref008],[@pone.0195687.ref018],[@pone.0195687.ref019],[@pone.0195687.ref021],[@pone.0195687.ref023],[@pone.0195687.ref024],[@pone.0195687.ref026],[@pone.0195687.ref028],[@pone.0195687.ref031],[@pone.0195687.ref032],[@pone.0195687.ref035],[@pone.0195687.ref037],[@pone.0195687.ref039],[@pone.0195687.ref046],[@pone.0195687.ref047],[@pone.0195687.ref049],[@pone.0195687.ref051],[@pone.0195687.ref052],[@pone.0195687.ref060],[@pone.0195687.ref063],[@pone.0195687.ref064],[@pone.0195687.ref068],[@pone.0195687.ref072],[@pone.0195687.ref075],[@pone.0195687.ref078],[@pone.0195687.ref079],[@pone.0195687.ref081],[@pone.0195687.ref086]\], which reported 34 estimated rates. The median lifetime prevalence for persons across these studies was 7.49 per 1000, and the 10% and 90% quantiles ranged from 3.62 to 19.67 per 1000 (a 5.43-fold difference) ([Table 5](#pone.0195687.t005){ref-type="table"}).

Although the high heterogeneity between the studies and the distribution of the prevalence rates themselves detract from the calculation of the mean effect, making use of the median advisable, we present the means below. Thus, the overall mean prevalence is 5.93 per 1000 (95% CI; 5.63--6.24). The mean prevalence for studies using point prevalence is 3.9 per 1000 (95% CI, 3.28--4.52). The 12-month prevalence is 4.56 per 1000 (95% CI, 4.09--5.03), and lifetime prevalence is 9.57 per 1000 (95% CI, 9.01--10.13). The forest plot for point, 12-month and lifetime prevalence are shown in Figs [2](#pone.0195687.g002){ref-type="fig"}--[4](#pone.0195687.g004){ref-type="fig"}.

![Forest plot point prevalence of psychotic disorders.](pone.0195687.g002){#pone.0195687.g002}

![Forest plot 12-month prevalence of psychotic disorders.](pone.0195687.g003){#pone.0195687.g003}

![Forest plot lifetime prevalence of psychotic disorders.](pone.0195687.g004){#pone.0195687.g004}

This review identified that the median estimate for point prevalence was lower when the case-finding setting was health and/or social services (3.11 per 1000) and 1.4-fold higher when the study was performed in the general population (4.44 per 1000). The median 12-month prevalence estimate from general population studies (4.40 per 1000) was 1.2-fold higher than from attended population studies (3.70 per 1000). Similarly, the lifetime prevalence rates were 1.5-fold higher in general population studies (8.03 per 1000) than in attended population studies (5.21 per 1000).

Prevalence estimates were obtained from different methods of confirming diagnoses. The point prevalence median range was from a maximum of 6.80 per 1000 when the SCID was used, to a minimum of 3.04 per 1000 when CIDI were used (2.24-fold difference). Conversely, in the 12-month prevalence studies, the rate was higher when CIDI were used (4.94 per 1000), and the lowest median prevalence estimate (3.70 per 1000) was with the clinical diagnosis. Likewise, the lifetime prevalence studies group showed the highest median prevalence using other instruments to confirm the diagnosis of psychosis (8.8 per 1000) and the lowest when using the clinical criteria (5.82 per 1000).

In the point prevalence studies, the highest median estimate of 4.21 per 1000 was found when the DSM was used, while this figure was 1.2-fold lower when the ICD was used with a median of 3.60 per 1000. In the studies that calculated 12-month prevalence rates, the ICD diagnostic classification system presented slightly a lower median estimate of 3.96 per 1000, while with the DSM this figure was 4.20 per 1000. In the lifetime prevalence studies, the DSM classification was the most often used and offered a higher median estimate of 7.19 per 1000 compared to that of the ICD which was 6.71 per 1000.

Each diagnosis category displayed differences in point prevalence rate estimates. When studies included schizophrenia and related disorders, the median estimated rate was lower (2.62 per 1000) than when schizophrenia only was analyzed (3.46 per 1000 inhabitants), non-affective psychoses was higher (4.53 per 1000) and the highest was probable psychosis (5.10 per 1000). In 12-month prevalence estimates, the highest median estimated rate was similar in non-affective psychosis and probable schizophrenia (4.5 and 4.35 per 1000), lower for schizophrenia and related disorders (4.26 per 1000) and the lowest for schizophrenia only (3.7 per 1000). The highest median estimate of lifetime prevalence was probable psychosis (17.24 per 1000), followed by schizophrenia and related disorders (8.8 per 1000), non-affective psychosis (8.18 per 1000) and schizophrenia only (6.35 per 1000).

When the point prevalence estimates for persons were divided into quality score quantiles, the median quality score and corresponding IQR was 12.00 (IQR = 3.0) across the point and 12-month prevalence studies and 13.00 (IQR = 5) for the lifetime prevalence studies.

3.3 Association between methodological issues and the prevalence of psychotic disorders {#sec022}
---------------------------------------------------------------------------------------

The pooled prevalence rate of psychotic disorders revealed that heterogeneity in the studies was high (*I*^2^ = 99.8%). Therefore, it was considered important to examine and try to explain the possible methodological sources of heterogeneity that could be present in the studies included in the review. Accordingly, in this analysis we included the following variables: prevalence type, case-finding setting, method of confirming diagnosis, international classification of diseases, diagnosis categories and study quality.

The random-effects meta-regression analysis showed a significant effect for the prevalence type, with higher lifetime prevalence rates than the 12-month prevalence rates (p\<0.0001). Also, a higher study quality was associated with a lower estimated prevalence of psychotic disorders (p = 0.0002). On the other hand, the diagnosis category probable psychotic disorder presented a higher prevalence rate than schizophrenia (p = 0.022) as did the non-affective psychosis group compared to the schizophrenia only group (p = 0.0091) ([Table 6](#pone.0195687.t006){ref-type="table"}). Finally, studies conducted in the general population presented higher prevalence rates than those carried out in populations attended in health and/or social services (p = 0.0059). This analysis revealed that neither the disease classification used, nor the diagnosis instrument applied had a significant effect on the prevalence rate (results not shown). We have found that the proportion of the variance that is explained in the final adjusted model is 40.6%.

10.1371/journal.pone.0195687.t006

###### Results of the meta-regression.

Random-effects model sizes of the prevalence of psychotic disorders.

![](pone.0195687.t006){#pone.0195687.t006g}

  Variables                                               Coefficients   LCI       UCI       p
  ------------------------------------------------------- -------------- --------- --------- ----------
  Intercept                                               0.0108         0.0064    0.0152    \< .0001
  **Prevalence type**                                                                        
  12-month (reference)                                                                       
  Point                                                   -0.0006        -0.0025   0.0014    0.5537
  Lifetime                                                0.0050         0.0031    0.0070    \< .0001
  **Case-finding setting**                                                                   
  Population attended in any health service (reference)                                      
  General population                                      0.0028         0.0008    0.0047    0.0059
  **Diagnosis categories**                                                                   
  Schizophrenia(reference)                                                                   
  Schizophrenia and related disorders                     -0.0004        -0.0026   0.0019    0.7586
  Non-affective psychosis                                 0.0026         0.0006    0.0045    0.0091
  Probable psychotic disorders                            0.0042         0.0006    0.0078    0.0222
  **Quality of the studies**                              -0.0008        -0.0012   -0.0004   0.0002

I^2^ = 99.8%; R^2^ = 40.6

LCI = Lower bound of 95% Confidence Interval; UCI: Upper bound of 95% Confidence Interval

I^2^ = variability due to true heterogeneity

R^2^ = [Coefficient of Determination](http://www.linguee.com/english-spanish/translation/coefficient+of+determination.html)

3.4 Publication bias {#sec023}
--------------------

The results of the Egger's test showed no statistical differences (z = -0.6769,p = 0.4985) and the visual inspection of the funnel plot revealed the absence of publication bias.

Discussion {#sec024}
==========

To our knowledge, this is the first systematic review including a meta-analysis summarizing the study methodology used in estimating the prevalence of psychosis globally. In addition to updating the previous systematic reviews up to 2015, we have provided a summary of the prevalence estimates by methodology undertaken and presented results of a meta-regression analysis showing the methodological aspects of the studies that influenced the variability estimates. We have also presented the proportion of the variance that is explained in the final adjusted model. Previous systematic reviews focused mainly on the descriptive findings concerning several aspects of the prevalence of schizophrenia \[[@pone.0195687.ref005],[@pone.0195687.ref010],[@pone.0195687.ref011]\]. However, in our review we also applied a meta-regression analysis.

Our review identified 73 studies from the literature on the prevalence of schizophrenia and psychotic disorders in English and Spanish published over a 25-year period (1990--2015). We used the year 1990 as a cut-off to limit our search, following Simeone et al. \[[@pone.0195687.ref011]\] criteria which verified that no major studies were excluded prior this date. Additionally, as they also state, since the treatment, diagnostic criteria and guidelines of diseases changes over the years, it would be not be useful to include previous years. We focused on describing the methodology adopted in each study and its association with the variability of estimated prevalence rates of psychosis and related disorders. This approach confirmed differences in rates worldwide by prevalence type, case-finding setting, diagnosis category and study quality. Conversely, the method of confirming diagnosis and the international classification of diseases were not associated with the variability of the prevalence estimates.

4.1 Principal findings {#sec025}
----------------------

The descriptive results of the pooled median global prevalence of psychotic disorders was 4.6 per 1000 persons, while the median point and 12-month prevalence was 3.89 and 4.03 per 1000 persons respectively and the median lifetime prevalence was 7.49 per 1000 persons.

Meta-regression analysis showed the methodological aspects of the studies that influenced the variability of the prevalence estimates. Concerning prevalence type, lifetime prevalence was higher than 12-month prevalence (p\<0.0001). Studies developed in the general population presented higher prevalence estimates that those developed in a population attended in health and/or social services (p = 0.0059), the diagnosis categories of probable psychotic diagnoses (p = 0.022) and non-affective psychosis (p = 0.0091) both present higher estimate rates than the diagnosis of schizophrenia only. Finally, a higher study quality is associated with lower estimates of prevalence of psychotic disorders (p = 0.0002). Additionally, the publication bias analyses revealed the absence of bias, thus corroborating the robustness of our results.

4.2 Meaning of findings {#sec026}
-----------------------

The median point prevalence of psychotic disorders was 3.89 per 1000 persons. This estimate is consistent with the earlier systematic review of 188 studies by Saha et al. \[[@pone.0195687.ref010]\] who reported median point prevalence estimates of 4.6 per 1000 persons. However, our 12-month prevalence figures (4.03 per 1000 persons) were higher than the 3.3 per 1000 persons found in previous systematic reviews \[[@pone.0195687.ref010],[@pone.0195687.ref011]\]. We also found higher figures for median lifetime prevalence (7.49 per 1000) than the 4.0 and 4.8 found by Saha et al. and Simeone et al., respectively \[[@pone.0195687.ref010],[@pone.0195687.ref011]\]. Based on the central 80% of the estimates (10% to 90% quantiles), the present review found that the different types of prevalence estimates had from 4.5-fold (point and 12-month) to 7.9-fold (lifetime) variation. Our figures on variation are again higher that the figures found by Saha et al. \[[@pone.0195687.ref010]\], which were 3.4-fold (point) to 4.6-fold (12-month) variation. In the systematic review by Goldner et al. \[[@pone.0195687.ref005]\], based on the 100% estimates (not the central 80%), a 5-fold variation for 12-month and lifetime prevalence for psychotic disorders was observed.

The following step is to determine how much of this variation is due to measurement error (methodological aspects). Thus, as methodology-dependent factors likely lead to variations in published estimates, the present review used a meta-regression analysis to determine the estimated effect size attributable to these factors.

Our findings suggest that four methodological factors (prevalence type, case-finding setting, diagnostic categories and study quality) contribute 40.6% of the variance in prevalence estimates. As with other systematic reviews of prevalence estimates, a significant heterogeneity (Q with p \< .0001) explored by *I*^2^ was found in the measurement of prevalence rates that were incompletely explained by meta-regression. These results are described below.

Our results show that the mean lifetime prevalence estimates for psychotic disorders are significantly higher than the mean 12-month prevalence estimates (p\<0.0001). It is reasonable to assume that lifetime prevalence should be higher than 12-month prevalence, as the study period in the first case includes all one's life up to the time of assessment, which implies that most cases can be found. Surprisingly, however, the data from the review by Saha et al. \[[@pone.0195687.ref010]\] does not support this assumption. We found similar estimates in both the point and 12-month prevalence types, which suggest that in a chronic disease such as schizophrenia, assessing these prevalence types does not affect estimates.

The choice of study setting (e.g. general population versus attended in health and/or services population studies) does play an important role in identifying those persons with a mental health disorder such as psychosis. Studies conducted in the general population present higher prevalence rates (p = 0.0059) than those carried out in populations attended in health/social services. This result is in agreement with the study by Saha et al. \[[@pone.0195687.ref010]\] that concluded that the use of an exhaustive method to identify cases such as door-to-door surveys or interviews based on several community information sources could identify more cases than those using few sources of information. Simeone et al. \[[@pone.0195687.ref011]\] also found different results according to the scope of the study, in the sense that, in studies that included only hospitalized patients, the prevalence figures were up to 60% lower than those that included patients treated both at the hospital and outpatient levels.

One explanation for higher prevalence rates of schizophrenia in general population studies is that previous studies have shown lay-administered interviews overestimate prevalence (e.g. NCS-R) \[[@pone.0195687.ref048]\]. And it is now widely appreciated that many otherwise healthy individuals in the community report experiencing isolated psychotic experiences (e.g. lifetime prevalence = 5.8%) \[[@pone.0195687.ref089]\].

Cross-sectional population-based study designs for low-prevalence disorders, such as psychosis, present some drawbacks \[[@pone.0195687.ref004],[@pone.0195687.ref009]\]. In this type of study it will be necessary to identify and evaluate many healthy people to reach a representative sample for reliable results \[[@pone.0195687.ref004]\]. Also, interviews of community members by mental health professionals for symptoms indicative of schizophrenia are time-consuming and expensive to conduct. Moreover, people with schizophrenia are probably less likely to be available for interview, or to agree to an interview if contacted. We agree that the most accurate way to assess schizophrenia and related disorders prevalence would involve full clinician interviews with the entirety of a population. However, since this is not practical in studies with large samples, a more cost-effective strategy could be to identify potential cases in a representative sample of the study population and subsequently carry out clinical interviews to confirm the diagnosis of those subjects to include them in the study \[[@pone.0195687.ref011]\]. One solution is to perform studies similar to the survey by Perälä et al. in Finland \[[@pone.0195687.ref008]\] in which they concluded that the use of many sources of information are crucial to attain precise figures of the lifetime prevalence of psychotic disorders, reporting a lifetime prevalence greater than 3%. Additionally, Moreno-Küstner et al., \[[@pone.0195687.ref058]\] developed a primary study of persons with schizophrenia and related disorders, based on a range of large health services databases including inpatient and outpatient records, emergency services and general practitioner surveys to attain accurate figures.

Concerning diagnosis categories, as was expected, meta-regression confirmed that the broader category of probable psychosis (p = 0.022) and non-affective psychosis (p = 0.0091) had a higher prevalence than the diagnosis of schizophrenia only. This result is in agreement with the study by Simeone et al. \[[@pone.0195687.ref011]\] which showed that there could be a prevalence increase of more than 70% when using a more comprehensive definition of the spectrum of \"schizophrenia and associated disorders\" compared to a narrower definition. Heterogeneity remained high in the probable psychosis category, but we chose a pragmatic approach to the diagnosis of psychotic disorders, given changing classification over time and between studies. This approach has construct validity with overall pooled prevalence rates \[[@pone.0195687.ref090]\].

We found that the quality of the study had an impact on prevalence estimates. Thus, improved study quality was associated with lower prevalence estimates (p = \< .0001). This result is similar to that found in the study by Simeone et al. \[[@pone.0195687.ref011]\] in which prevalence rates were higher in studies with low levels of quality, which probably indicates that the actual prevalence rate of schizophrenia is lower than that offered in those studies with low quality. However, although we used the method developed by Saha et al. \[[@pone.0195687.ref010]\] to assess certain items concerning the quality of the original data, our results conflict with those of Saha et al. \[[@pone.0195687.ref010]\] who found that studies with higher overall quality scores tended to identify more cases and thus generate higher prevalence estimates than lower quality studies. Future studies could explore the impact of quality on the variation in prevalence estimates.

No differences were found between the methods of confirming diagnoses. Our results show that the method chosen to confirm the diagnosis was not associated with the variability of the prevalence estimates. This is very important, as it implies that any of the instruments mentioned below, patient interviews or clinical judgment may be used to confirm the diagnosis as this factor does not play an important role in the prevalence estimates.

In order to count the disorders of interest, it is essential to have reliable diagnostic criteria to define cases. Several validated instruments are available for the assessment of a range of mental disorders. These include the CIDI \[[@pone.0195687.ref091]\], SCID \[[@pone.0195687.ref092]\], SCAN \[[@pone.0195687.ref093]\], and the Mini-International Neuropsychiatric Interview \[[@pone.0195687.ref094]\]. A significant advantage of a number of these instruments is that they are designed to be administered by trained lay-interviewers allowing for rapid surveying of large samples. The instruments used may vary from brief symptom checklists used in the clinical diagnoses made by the professional, to fully standardized surveys, and finally, the gold standard of the clinical interview.

This review sought epidemiological data for mental disorders defined according to DSM or ICD diagnostic criteria. We found no differences associated with any of these international classifications in the prevalence estimates. We have analysed the moderating effect of different versions of the classification of diseases (ICD; 8th, 9th and 10th and DSM; III, IV). We have included them in the bi-variate analyses but found no association with the dependent variable. Simeone et al. \[[@pone.0195687.ref011]\] found only minor differences in prevalence estimates of schizophrenia calculated using different diagnostic criteria such as ICD-9 vs. ICD-10. This result has an important implication for research on psychotic disorders, which is that using ICD or DSM classification is not associated with prevalence estimates. Further research using DSM-5 should be carried out to confirm this result.

4.3 Limitations {#sec027}
---------------

Although we used a comprehensive search and selection strategy of the published literature based on a validated and reliable methodology to minimize missed studies, we had no help in designing or conducting the search from informaticians or documentalists, so a number of data gaps became evident in the course of conducting this review. Another limitation is the exclusion of non-English and non-Spanish literature. However, cross-checking English abstracts of excluded studies showed that few studies (including no major studies) were missed given the language restriction which appears to reflect that studies today are commonly published in English. Furthermore, the age range of the study samples included in this review varied greatly, which limited our ability to use age range as a variable for sub-analyses. The scope of this review was restricted only to general populations or out-patients attended in health and/or social services, rather than including focused populations such as institutionalized or incarcerated patients, homeless persons, and migrants. Special populations such as these do have a higher reported prevalence of psychotic disorders so the prevalence rates could be higher than the rate reported here. But these rates should be described separately, so as not to overestimate the prevalence in the general population. Finally, since the methodologies of the individual studies present large differences, pooled effect sizes should be interpreted in line with corresponding *I*^2^ statistics \[[@pone.0195687.ref095]\].

4.4 Conclusions and practical implications {#sec028}
------------------------------------------

Despite the wide variation in the methodological components of the studies reviewed, these data indicate that approximately one in 150 individuals will be diagnosed with psychosis disorders at some point during their lifetime. Prevalence estimates across studies varied when looking at different periods of assessment, study design setting, diagnosis categories and quality scores. Thus, a well-designed epidemiological study with homogeneous methodology will help to improve our understanding of the global prevalence of this disease.

One of the principal clinical implications is that when a systematic review of these types of data is conducted rigorously and data analyzed appropriately, these reviews can be of great benefit to healthcare professionals and policy makers. This evidence suggests that a focus on a sub-group of studies that meet a number of criteria (e.g. study quality, prevalence type, setting design) may provide a better reflection of the true prevalence of psychosis.

This updated review provides vital evidence on the epidemiology of psychosis in general and attended populations, which is important information for healthcare planning. The present review provides an overall comprehensive comparison of methodologies used in psychotic disorders prevalence studies, which could generate insightful information for future epidemiological studies in adopting the relevant methodological approach.
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